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Abstract
Non-alcoholic fatty liver disease (NAFLD) affects about a quarter of the world’s population and it is closely linked to hyper-
tension (HT). Pro-inflammatory and anti-inflammatory cytokines play a key role in the pathology progression, and the search for 
non-invasive biomarkers for the diagnosis of NAFLD remains an important issue.
The aim of the study was to determine the diagnostic and prognostic value of IL-1β and IL-10 in assessing the progression 
of liver parenchyma changes in patients with NAFLD and HT comorbidity.
Materials and methods. A study of 115 patients with non-alcoholic steatohepatitis (NASH) was performed. The main group 
consisted of 63 patients with NASH and HT, 52 patients with isolated NAFLD represented the comparison group. Clinical and labo-
ratory parameters were evaluated, IL-10 and IL-1β levels were measured by ELISA method, ultrasound steatometry and elastography 
were performed in all patients.
Results. The attenuation coefficient and median liver stiffness in NAFLD and HT group significantly exceeded the results 
in the isolated NAFLD group and in the control group. The IL-1β level in NAFLD and HT group was 17.55 pg/ml, and in isolated 
NAFLD group the indicator averaged 15.72 pg/ml, which exceeded the control values (8.26 pg/ml). IL-10 level was 12.69 pg/ml 
and 14.34 pg/ml in patients with comorbid and isolated NAFLD, respectively, while control results averaged 16.19 pg/ml. It were 
found strong relationship between IL-1β, IL-10 and CRP levels in patients with NAFLD and HT (r = 0.61, p = 0.024, and r = –0.69, 
p = 0.036, respectively). Inverse correlations were also found between the cytokines IL-1β and IL-10 in NAFLD patients with and 
without HT (r = –0.61, p < 0.001, and r = –0.57, p < 0.001, respectively). Changes in the cytokine status of patients with NAFLD at 
different stages of steatosis and liver fibrosis had been identified.
Conclusions. The presence of concomitant HT in patients with NAFLD is associated with greater severity of liver paren-
chyma changes. NAFLD manifestation is accompanied by increase of IL-1β and decrease of IL-10 levels, and deepening of these 
deviations were found in patients with comorbidity of NAFLD and HT.
Interleukins IL-1β and IL-10 can be defined as biomarkers of NAFLD progression both in its isolated course and in its comor-
bidity with HT. The possibility of using biomarkers as an independent non-invasive test of diagnosing NAFLD requires further study.
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1. Introduction
Non-alcoholic fatty liver disease is the most common cause of chronic liver dysfunction. The 
prevalence of the disease worldwide averages about 25 % with wide variations depending on the 
region [1, 2]. The disease covers a wide range of histological pathologies from simple steatosis to 
non-alcoholic steatohepatitis (NASH), which affects 1.5–6.45 % of the population, liver fibrosis that 
develops in more than 40 % of patients with NASH, liver cirrhosis and hepatocellular carcinoma [3].
The probable role of NAFLD as a risk factor for cardiovascular disease remains a debat-
able question, so special attention is paid to the comorbidities of fatty liver and disorders of the 
cardiovascular system [1, 4]. In particular, the combination of NAFLD and hypertension (HT) is 
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an important issue, as NAFLD affects about 50 % of patients with high blood pressure [5]. The re-
sults of studies indicate a bidirectional relationship between HT and fatty liver infiltration through 
common pathogenetic links, such as systemic inflammation, obesity, disorders of lipid and carbo-
hydrate metabolism and oxidative stress. These data form the basis for considering the disease as 
equal and interdependent components of the metabolic syndrome [6, 7].
NAFLD is known to be associated with inflammatory processes in the liver, and cytokines 
play an important role in its pathogenesis. In recent years, the importance of interleukin-1β (IL-1β) 
in the development of NAFLD has been actively studied. It is known that its activity increases in 
patients with NASH and correlates with the severity of fatty infiltration of the liver [8–10]. 
At the same time, there is evidence that interleukin-10 (IL-10) is involved in various bio-
chemical processes as an anti-inflammatory cytokine. It is produced to protect against excessive 
immune response, limits organ damage, in particular, plays a protective role in liver fibrogenesis 
and prevents the progression of hepatic steatosis. [11–13]. In the liver, IL-10 was detected in hepato-
cytes, stellate cells, and Kupffer cells, but only a few studies have been performed to investigate the 
role of endogenous IL-10 in the progression of NAFLD [14]. Cytokine IL-10 levels have been shown 
to be significantly reduced in patients with metabolic syndrome and chronic liver disease [14, 15].
Characteristic changes in cytokine levels are also observed in patients with persistently 
elevated blood pressure. Research suggests that hypertension is associated with increased produc-
tion of pro-inflammatory cytokines, including IL-1, which may be considered a potential mediator 
of inflammatory complications of hypertension [16]. In the meanwhile, IL-10 exhibits protective 
activity under conditions of hypertension, as it counteracts both the pressor activity of Angiotensin 
II-mediated reactions and vascular dysfunction associated with hypertension [17].
Various studies suggest that patients with NAFLD have an imbalance of pro-inflammatory 
and anti-inflammatory cytokines, and its severity increases with the progression of changes in the 
liver parenchyma [11]. Therefore, the determination of pro-inflammatory and anti-inflammatory 
interleukins activity can play a significant role in the diagnosis of NAFLD progression, in particu-
lar, in combination of NAFLD and HT. 
The aim of our study was to determine the diagnostic and prognostic value of IL-1β and 
IL-10 in assessing the progression of liver parenchyma changes in patients with NAFLD and 
HT comorbidity.
2. Materials and methods
The research was conducted on the basis of the Department of Internal Medicine No. 1 of 
Kharkiv National Medical University from September 1, 2018 to January 31, 2020. The study was 
approved by the Ethics and Bioethics Commission of Kharkiv National Medical University (proto-
col No. 8 on October 03, 2018). The experimental part of this study respects the ethical standards in 
the Helsinki Declaration of 1975, as well as the principles of Good Clinical Practice (GCP) and the 
national law. All patients voluntarily participated in the study and signed the Consent to Participate 
in a Research Study.
We observed 115 patients with NAFLD at the stage of non-alcoholic steatohepatitis (NASH). 
Among the examined patients were 57 men and 58 women aged 38 to 59 years (M = 48.4, 95 % 
CI [47.4, 49.3]). Patients were divided into two groups depending on the presence of concomitant hy-
pertension. The main group (n = 63) consisted of 32 men and 31 women aged 38 to 59 years (M = 48.4, 
95 % CI [47.2, 49.6] with NAFLD on the background of HT, and the comparison group (n = 52) con-
sisted of 25 men and 27 women aged 39 to 59 years (M = 48.3, 95 % CI [46.8, 49.8] with isolated 
NAFLD. The groups had no differences in age (p = 0.908), gender composition (p = 0.772). 
The control group (n = 20) consisted of 12 women and 8 men aged 38 to 56 years (M = 47.1, 
95 % CI [45.1, 49.1], that were almost healthy volunteers, randomized by age (p = 0.394; p = 0.555) 
and sex (p = 0.400; p = 0.538).
The NASH was diagnosed in previous stages of the study based on laboratory and instru-
mental survey data according to the guidelines EASL-EASD-EASO, 2016. The diagnosis of HT 








All patients were calculated body mass index (BMI) according to the conventional formula: 
BMI = body weight (kg)/height (m2), and the values of office systolic (CAT) and diastolic (DAT) 
blood pressure were determined using a BP tonometer AG1-40 (Microlife AG, Switzerland) in 
accordance with current recommendations (ESH/ESC).
Plasma levels of interleukin-1β and interleukin-10 were determined by enzyme-linked im-
munosorbent assay using the Human IL-1β (Interleukin 1 Beta) ELISA Kit (Elabscience, USA) 
and the Human IL-10 (Interleukin 10) ELISA Kit (Elabscience, USA) in accordance. The level of 
the marker of the acute phase of inflammation of C-reactive protein (CRP) was determined using 
a highly sensitive method (hs-CRP ELISA) (Biomerica, USA).
Evaluation of steatosis and liver fibrosis was performed using an ultrasound scan-
ning system Soneus P7 (Ultrasign, Ukraine). The ultrasound steatometry was performed using 
the «AC» mode, the liver fat was quantified by measuring the value of the linear attenuation 
coefficient (AC; dB/cm) of ultrasound in the liver parenchyma with the following staging of 
fatty hepatosis.
The degree of fatty infiltration of the liver was evaluated on a validated scale scale (NAS – 
NAFLD activity score) and the Soneus P7 correspondence table (Table 1).
Table 1
Correspondence of Soneus P7 measurement results and steatosis stage according to NAS
Attenuation coefficient (AC-Medin, dB/cm) NAS Steatosis stage Hepatocytes with macrovesicular steatosis, %
1.0–2.19 S0 No steatosis from 0 to 5
2.2–2.29 S1 Mild steatosis > 5 to 33
2.3–2.9 S2 Moderate steatosis > 33
2.9–3.5 S3 Severe steatosis > 66
Shear wave elastometry and elastography were performed in the «SE» mode using a convex 
sensor 2–5 MHz with concordance determination of the liver stiffness (LS; kPa or m/s) to the fi-
brosis and cirrhosis stages according to the METAVIR scale (Castera et al.) [18] and the Soneus P7 
correspondence table (Table 2).
Table 2
Correspondence of Soneus P7 measurement results and liver fibrosis stages according to METAVIR scale
The median liver stiffness (LS-Median, kPa) METAVIR score Fibrosis stage Morphologic features
2.5–6.0 F0 No fibrosis No fibrosis
6.0–7.0 F1 Weak fibrosis Star-shaped expansion of portal tracts by fibrosis without septal formation
7.0–9.5 F2 Mild fibrosis Portal tracts expansion with single porto-portal septa ( > 1 sept)
9.5–12.5 F3 Severe fibrosis Numerous port-central septa
12.5–60 F4 Cirrhosis Cirrhosis
The obtained results were statistically processed using computer programs «Excel 2019» (Mi-
crosoft), «STATISTICA 8.0» (StatSoft Inc.). Continuous values were presented as mean (M) or me-
dian (Me) according to the sample of the law of normal distribution and confidence intervals (CI) 
with a given reliability γ = 0.95 (95 % CI). The statistical significance of the differences between 
the numbers of results in the groups was confirmed by Pearson’s χ2 test. Significant differences bet-
ween the levels of parameters in the two groups were determined using the Mann-Whitney U-test.
The relationships between the results were determined using Spearman’s rank correlation 
coefficient (r), and the correlation was assessed according to the Evans scale [19]. The results of all 
statistical analysis procedures were considered reliable at a significance level of p < 0.05.
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Anthropometric examination of patients showed that BMI in the groups with NAFLD 
and HT comorbidity and isolated NAFLD had no significant differences, but in both groups 
significantly exceeded similar control values. Blood pressure values differed significantly between 
groups (Table 3).
Table 3
Clinical and laboratory characteristics of the examined patients
Indicator NAFLD+HT (n = 63) NAFLD (n = 52) Control group (n = 20) Reliability  between groups




























Note: p < 0.05 – the difference is statistically significant between groups; р1–2 – the difference between the NAFLD+HT group and 
the isolated NAFLD group; р1–3 – the difference between the NAFLD+HT group and the control group; р2–3 – the difference between 
the isolated NAFLD group and the control group
During the study of cytokine status, it was found that IL-1β levels in patients with comor-
bidity of NAFLD on the background of HT significantly exceeded the corresponding values in the 
group with isolated NAFLD, and in general the level of inflammatory marker in patients of the 
main group and comparison group exceeded control values 2.1 and 1.9 times, respectively. At the 
same time, the level of the anti-inflammatory biomarker IL-10 in patients with isolated NAFLD 
significantly exceeded similar indicator of patients with a combination of NAFLD and HT, and 
anti-inflammatory activity of cytokine was higher in the control group in comparison with all 
patients with NAFLD (Table 3).
Significant differences in the indicators of steatosis and liver fibrosis in patients with 
comorbidity and isolated course of NAFLD were revealed, as well as the indicators differed signi-
ficantly from the control results.
According to the results of ultrasound steatometry, the attenuation coefficient in NAFLD 
and HT group averaged 2.55 dV/cm (95 % CI [2.50, 2.65]), that was 1.13 and 1.4 times greater, 
than in isolated NAFLD patients (2.24 dV/cm (95 % CI [2.31, 2.43], p < 0.001) and in the control 
group (1.82 dV/cm (95 % CI [1.72, 1.90], p < 0.001), respectively (Fig. 1).
The average liver stiffness in patients with comorbidity of NAFLD and HT was 
7.24 kPa (95 % CI [7.09, 7.84], which significantly exceeded the results in the isolated NAFLD 
group (5.97 kPa (95 % CI [5.61, 6.53], p < 0.001) and in the control group (5.02 kPa (95 % 
CI [4.94, 5.21], p < 0.001) (Fig. 2).
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Fig. 1. The results of ultrasound steatometry: the value of the linear attenuation  
coefficient in the examined patients
Fig. 2. The results of shear wave elastometry: the value of the average liver  
stiffness in the examined patients
Ranging of liver steatosis and fibrosis in the examined patients according to the NAS and 
METAVIR scales revealed that severity of fatty infiltration of liver parenchyma (p = 0.005) and 
fibrotic liver changes severity (p < 0.001) increases in conditions of accession HT to NAFLD. How-
ever, the number of patients at the stage of F3 fibrosis in both groups did not differ, which indicates 
an inessential effect of high blood pressure on severe liver fibrosis development (Table 4).
Evaluation of the correlations between cytokines and the marker of acute inflammation 
revealed a strong direct relationship between the content of IL-1β and CRP and a strong inverse re-
lationship between the level of IL-10 and CRP in patients with NAFLD and HT (r = 0.61, p = 0.024 
and r = –0.69, p = 0.036, respectively) (Fig. 3).
In the group with isolated NAFLD, inverse correlations between IL-10 and CRP were con-
sidered as weak (r = –0.30, p = 0.029), and no statistically significant interaction between IL-1β and 
CRP was found (p = 0.295), which proves the significance of concomitant hypertension in proces-






















Distribution of examined patients according to the stages of steatosis and liver fibrosis
Steatosis and fibrosis 
stages
NAFLD and HT (n = 63) NAFLD (n = 52) Reliability of difference  
(Pearson’s c2 test results)n % n %
Steatosis stages
S1 20 31.75 29 55.77 p = 0.010
p = 0.005S2 27 42.86 20 38.46 p = 0.634
S3 16 25.40 3 5.77 p = 0.005
Fibrosis stages
F0 4 6.35 21 40.38 p < 0.001
p < 0.001
F1 20 31.75 18 34.61 p = 0.745
F2 33 52.38 12 23.07 p = 0.002
F3 6 9.52 1 1.92 p = 0.090
Note: p < 0.05 – the difference is statistically significant between groups
Fig. 3. Correlations between cytokine levels and C-reactive protein content  
in patients with NAFLD and HT
Strong and moderate inverse correlations were also found between the cytokines IL-1β and 
IL-10 in NAFLD patients with and without concomitant hypertension (r = –0.61, p < 0.001, and 
r = –0.57, p < 0.001, respectively) (Fig. 4).
Fig. 4. Correlations between cytokine levels in both groups of patients with NAFLD
Analysis of the biomarkers levels by stages of hepatic steatosis among the examined patients 
revealed that pro-inflammatory activity of IL-1β was significantly increased with the progres-
sion of steatosis in patients with a combination of NAFLD and HT. However, the IL-1β level in-
creased statistically in patients with isolated NAFLD only during the progression of steatosis from 
stage S1 to S2 (Table 5).
IL-10 levels also decreased significantly with increasing fatty liver infiltration severity in 









activity of plasma proteins in these conditions. The obtained results suggest a decrease in anti-inflam-
matory activity with a simultaneous increase in the pro-inflammatory effect of plasma proteins with 
the progression of hepatic steatosis, especially with the additional effect of HT on the NAFLD course.
Ranging of patients by liver fibrosis stages in the analysis of plasma biomarker levels re-
vealed an increase in the IL-1β activity with a sharp decrease in the content of IL-10 starting from 
stage F2 by METAVIR classification. In the group of isolated NAFLD patients, statistically sig-
nificant differences were observed only between the stages of liver fibrosis F2 and F3, which may 
indicate an additional effect of HT on the severity of anti-inflammatory and pro-inflammatory 
activity of biomarkers in NAFLD (Table 6).
Table 5
Biomarker levels in the examined patients depending on the hepatic steatosis stage according to the NAS 
classification
Indicator Steatosis stage


































































16.12, 95 % 
CI [3.33, 24.83]
Note: p < 0.05 – the difference is statistically significant between groups; р1–2 – the difference between patients with hepatic steato-
sis in stages S1 and S2; р1–3 – the difference between patients with hepatic steatosis in stages S1 and S3; р2–3 – the difference between 
patients with hepatic steatosis in stages S2 and S3
Table 6
Interleukin levels in the examined patients depending on the liver fibrosis stage according to METAVIR
Indicator Fibrosis stage
































































































10.05, 95 % 
CI [10.05, 10.05)
Note: p < 0.05 – the difference is statistically significant between groups; р1–2 – the difference between patients with F0 and F1 liver 
fibrosis; р1–3 – the difference between patients with F0 and F2 liver fibrosis; р1–4 – the difference between patients with F0 and F3 
liver fibrosis; р2–3 – the difference between patients with F1 and F2 liver fibrosis; р2–4 – the difference between patients with F1 and 
F3 liver fibrosis; р3–4 – the difference between patients with F2 and F3 liver fibrosis
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Determination of the relationship between cytokines and indicators of the liver parenchyma 
in patients with comorbid NAFLD showed direct moderate correlations between IL-1β and AC-Me-
dian (r = 0.53, p < 0.001) and the LS-Median (r = 0.53, p < 0.001), while in the group with isolated 
NAFLD the corresponding correlations were weak (r = 0.39, p = 0.005, and r = 0.30, p = 0.029, re-
spectively). At the same time, the correlations between the anti-inflammatory cytokine IL-10 and 
the indicators of liver parenchyma changes were inverse and moderate in patients with NAFLD 
and HT (r = –0.43, p < 0.001 with AC-Median and r = –0.58, p < 0.001 with LS-Median), and in 
the isolated NAFLD group they were less pronounced (r = –0.44, p = 0.01 and r = –0.39, p = 0.04, 
respectively).
4. Discussion
Our findings on the relationship between cytokines and liver parenchymal status confirm the 
data of Nelson J., Bocsan, I. et al. that pro-inflammatory cytokines levels, such as IL-1β, are elevated 
in non-alcoholic steatohepatitis [9, 14, 20, 21]. The literature also suggests that its high levels con-
tribute to the development of hepatic steatosis and fibrosis of the liver parenchyma, and low levels 
of IL-10 allow to produce pro-inflammatory cytokines and cause chronic inflammation [8, 9, 11]. 
The data indicate that the cytokine IL-10 levels decreases with deepening of steatosis chan-
ges according to NAS classification in the comorbidity of NAFLD and HT group. However, in 
patients with isolated NAFLD IL-10 decreases only in the transition of steatosis from stage S1 
to S2, and even slightly increases in patients with stage S3 steatosis.
These ambiguous results regarding the anti-inflammatory activity of IL-10 among the 
examined patients partially confirm the opinion of different authors that the cytokine IL-10 exhi-
bits different phenotypic effects. 
Thus, Saraiva M. et al. investigated that its antifibrotic activity is detected only at the be-
ginning of the disease, and with the progression of NAFLD this cytokine can stimulate irreversible 
changes in the liver parenchyma due to the complexity of the fibrogenesis process and different 
effects of IL-10 [15]. Steen E. H. et al. also concluded that the anti-inflammatory effects of IL-10 
are more pronounced in acute inflammation, and during chronic processes the cytokine can lead to 
tissue damage and deepen inflammatory changes [13]. These data confirm our results, which are 
associated with an unexpected increase in IL-10 in patients with NAFLD at the stage of steatosis S3.
Study limitations. Patients with other diffuse and focal liver diseases (alcoholic fatty liver 
disease, viral hepatitis, liver cirrhosis, etc.), HT III stage, 3 grade, symptomatic HT, coronary heart 
disease, diabetes mellitus and other endocrine pathologies, oncological diseases, systemic connec-
tive tissue diseases, acute and chronic internal inflammatory diseases were not included in study. 
We also didn’t study the characteristics of cytokines in patients with NAFLD at the stage of severe 
fibrosis (F4), cirrhosis and hepatocellular carcinoma.
Prospects for further research. Therefore, despite certain inverse correlations between 
IL-10 and acute inflammatory markers and indicators of the liver parenchyma conditions, the cy-
tokine anti-inflammatory effect requires further more detailed study depending on the NAFLD 
history and other links of pathogenetic influence on metabolism in this category of patients. 
5. Conclusions
The presence of concomitant HT in patients with NAFLD is associated with significantly 
greater severity of fatty infiltration and fibrotic changes in the liver parenchyma. This is evidenced 
by a significant decrease in the mild steatosis (S1) and fibrosis (F0) incidence with a corresponding 
increase in the number of cases represented by significant fatty (S3) and fibrotic (F2) changes in 
the liver in patients with NAFLD on the background of HT.
NAFLD manifestation is accompanied by a significant increased pro-inflammatory cyto-
kine IL-1β content and a decrease in the anti-inflammatory IL-10 concentration. In the meanwhile, 
the comorbidity of NAFLD and HT lead to a statistically significant deepening of these deviations.
The depth of change in cytokine status of patients with NAFLD and HT was also correlated 
with an increase in CRP concentration, which additionally emphasizes the importance of low-
grade systemic inflammation in pathogenesis of the comorbid course of NAFLD.
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The obtained data allow us to consider the interleukins IL-1β and IL-10 as biomarkers of 
NAFLD progression both in its isolated course and in its comorbidity with HT. However, due to the 
complexity of pathogenetic processes, in particular, the bidirectional effect of anti-inflammatory 
cytokine IL-10, the possibility of using biomarkers as an independent non-invasive test of diagnos-
ing NAFLD requires further study.
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